Wockhardt will deepen its novel antibiotics pipeline over the next five years and focus on building a biosimilar business for ...

AscellaHealth has introduced its latest Specialty & Rare Pipeline Digest™, a quarterly publication designed to provide ...

Growth in Specialty and Orphan Drug Approvals: The FDA’s focus on specialty medications and orphan drugs continues to expand, with 71% of recent submissions being for specialty medications and 34% for ...

AbbVie ABBV stock has gained 16.1% so far this year compared with an increase of 4.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.

Introduction Biosimilar monoclonal antibodies (mAbs) are biologic drugs designed to be highly similar to already approved reference monoclonal ...

More ‘biosimilar’ medicines should be brought to market in the EU because of a regulatory policy shift on the need to carry out expensive clinical efficacy studies, experts have said.

Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) today published its audited consolidated financial statements for the 2024 financial year and provided an outlook for fiscal year 2025 ...

We have the strongest in-house developed product pipeline in the biosimilar industry based on official available data. Ten products are in advanced development and additionally 18 molecules have ...

When looking for growth potential, we can especially mention the biosimilar pipeline of Fresenius. Not only did the sub-segment report high-growth rates in the last few quarters, but management is ...

We are pleased to expand our partnership with mAbxience as we advance our biosimilars pipeline,” said Chirag and Chintu Patel, Co-Chief Executive Officers of Amneal. “We have a longstanding ...

At the same time, our strong in-house R&D capabilities have put Alvotech in a leading position among pure play biosimilar companies in terms of the market value of our product pipeline.